The National Institute for Health and Care Excellence (NICE) has recommended Venetoclax with azacitidine from AbbVie, as an option for untreated Acute Myeloid Leukaemia in adults when intensive chemotherapy is unsuitable.
This study will compare two different treatments. Patients are assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza®, or an experimental medicine gilteritinib in combination with azacitidine.
The National Institute for Health and Care Excellence (NICE) in preliminary guidance does not recommend Vidaza (azacitidine) from Celgene as...
Azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), • chronic myelomonocytic leukaemia (CMML) with 10 % to 29 % marrow blasts without myeloproliferative disorder, • acute myeloid leukaemia (AML) with 20 % to 30 % blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification, • AML with > 30 % marrow blasts according to the WHO classification.
The FDA has approved ivosidenib (Tibsovo) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.